The UK and US have signed a major trade agreement that will guarantee zero import taxes on UK drug products going into the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise spending on medicines through the National Health Service (NHS). This move ensures that import taxes on these crucial products will be held at zero for a timeframe of three years.
This agreement is in response to earlier threats to hike import taxes on patented drug imports, with potential rates floated reaching one hundred percent.
"This agreement between the Britain strengthens the global environment for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," an announcement said.
Economic Importance
Medicines are one of the UK's biggest exports to the America, which is by far the primary destination for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of September, the UK shipped medicines totaling billions to the US. This value represented a significant portion of total UK exports in that span.
"This guarantee secures work, increases capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a government official commented.
Detailed UK Commitments
The deal involves several key pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to increase overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, refunds exceeded 20%.
Broader Context
The deal comes amid a ongoing dispute between the drug companies and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that American patients were paying significantly more for the identical medicines than people in the other developed nations.
Recently, several significant manufacturing plans in the UK have been paused or cancelled, while major investments have been pledged toward US facilities.
The Science Minister stated that the NHS must spend more on medicines, noting that its budget allocation on drugs had shrunk as a share of its resources over the past decade.
